期刊文献+

miR-1-3p在食蟹猴心肌损伤中表达水平及其与CK-MB、cTnI和NT-proBNP的相关性 被引量:3

Expression of miR-1-3p in myocardial injury cynomolgus monkey and its correlation with CK-MB,cTnI and NT-proBNP
下载PDF
导出
摘要 目的探讨循环miR-1-3p在多柔比星诱导食蟹猴心肌损伤模型中的表达水平和诊断价值。方法选取3~5岁普通级雄性食蟹猴17只,随机分为对照组(7只)和实验组(10只),静脉注射盐酸多柔比星注射液(2.5 mg/kg)4周,收集外周血浆标本和心脏组织标本,应用液相芯片技术测定肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)和NT-proBNP表达水平,且应用实时定量PCR技术测定miR-1-3p表达的水平,并进行相关性分析。结果成功建立药物致食蟹猴心肌损伤模型;两组CK-MB、cTnI和NT-proBNP水平比较差异有统计学意义(P<0.05);实验组miR-1-3p的表达水平在给药4周后较给药前和对照组相比明显升高(P<0.05);miR-1-3p的表达水平与CK-MB、cTnI和NT-proBNP改变呈现了相同的升高趋势,且二者之间具有明显相关性。结论miR-1-3p可作为药物引起心肌损伤的生物学诊断标志物之一。 Objective To investigate the expression level and diagnostic value of circulating miR-1-3 p in doxorubicin-induced myocardial injury model of cynomolgus monkey.Methods Totally 17 normal male cynomolgus monkeys aged 3~5 years were randomly divided into control group(n=7)and experimental group(n=10).Doxorubicin hydrochloride injection(2.5 mg/kg)was injected intravenously for 4 weeks.The peripheral plasma samples and heart tissue samples were collected.The expression levels of CK-MB,cTnI and NT-proBNP were measured by liquid chip technology,the expression level of miR-1-3 p was determined by real-time quantitative PCR,and the correlation was analyzed.Results The myocardial injury model of cynomolgus monkey was established successfully.There were significant differences in the levels of CK-MB,cTnI and NT-proBNP between the two groups(P<0.05).The expression level of miR-1-3 p in experimental group was significantly higher than that in control group after 4 weeks of administration(P<0.05).The expression level of miR-1-3 p showed the same increasing trend with the changes of CK-MB,cTnI and NT-proBNP,and there was a significant correlation between them.Conclusion miR-1-3 p can be used as one of the biomarkers of myocardial injury caused by drugs.
作者 姜惠敏 惠汝太 汪巨峰 JIANG Hui-min;HUI Ru-tai;WANG Ju-feng(Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University,Beijing 100010,China;National Center for Safety Evaluation of Drugs,National Institutes for Food and Drug Control,Beijing 100176,China;Fuwai Hospital,Chinese Academy of Medical Sciences,State Key Laboratory of Cardiovascular Disease,Beijing 100037,China)
出处 《实用药物与临床》 CAS 2020年第3期203-206,共4页 Practical Pharmacy and Clinical Remedies
基金 国家科技部“十二五”重大新药创制课题(2012ZX09302001) “十二五”新药研究开发关键技术研究课题(2012ZX09505001004)。
关键词 心肌损伤 生物学标志物 MICRORNA-1 心肌肌钙蛋白I 肌酸激酶同工酶 N末端B型利钠肽前体 Myocardial injury Biomarker MicroRNA-1 Cardiac troponin I Creatine kinase isoenzyme N-terminal B-type natriuretic peptide
  • 相关文献

同被引文献37

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部